Benzinga
Published Mar 22, 2024 16:00
Updated Mar 22, 2024 17:10
Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Eli Lilly and Co (NYSE:LLY) and its primary competitors in the Pharmaceuticals industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
Eli Lilly and Co Background Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Eli Lilly and Co | 132.80 | 67.94 | 20.39 | 19.91% | $3.03 | $7.57 | 28.1% |
Novo Nordisk A/S | 47.87 | 37.33 | 17.25 | 22.01% | $28.51 | $55.85 | 36.95% |
Johnson & Johnson | 29.95 | 5.46 | 4.68 | 5.78% | $6.82 | $14.6 | 7.3% |
Merck & Co Inc | 883 | 8.33 | 5.24 | -3.11% | $-0.77 | $10.72 | 5.78% |
AstraZeneca PLC | 34.75 | 5.24 | 4.51 | 2.52% | $2.18 | $9.72 | 7.29% |
Novartis AG | 23.43 | 4.21 | 4.31 | 19.99% | $4.18 | $8.75 | 7.39% |
Pfizer Inc | 74.76 | 1.76 | 2.67 | -3.62% | $-1.77 | $6.69 | -41.34% |
Sanofi SA | 20.44 | 1.48 | 2.38 | -0.75% | $0.42 | $8.15 | 6.5% |
Bristol-Myers Squibb Co | 13.37 | 3.54 | 2.38 | 6.03% | $4.45 | $8.73 | 0.62% |
GSK PLC | 13.89 | 5.06 | 2.26 | 2.64% | $1.16 | $5.63 | 9.16% |
Zoetis Inc | 33.20 | 15.42 | 9.11 | 10.42% | $0.83 | $1.49 | 8.48% |
Takeda Pharmaceutical Co Ltd | 38.57 | 1.01 | 1.64 | 1.53% | $314.89 | $731.71 | 1.33% |
Viatris Inc | 240.20 | 0.70 | 0.94 | -3.7% | $-0.07 | $1.6 | -1.0% |
Dr Reddy's Laboratories Ltd | 19.32 | 3.76 | 3.72 | 5.29% | $22.42 | $42.2 | 6.57% |
Jazz Pharmaceuticals PLC | 20.35 | 2.07 | 2.33 | 2.61% | $0.29 | $0.9 | 4.1% |
Average | 106.65 | 6.81 | 4.53 | 4.83% | $27.4 | $64.77 | 4.22% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } By thoroughly analyzing Eli Lilly and Co, we can discern the following trends:
The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When examining Eli Lilly and Co in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.